Viral vectors for cystic fibrosis gene therapy: What does the future hold?

Virus Adaptation and Treatment

Volumn 2, Issue 1, 2010, Pages 159-171

  Griesenbach, Uta ^a   Alton, Eric W F W ^a   Inoue, Makoto ^b   Hasegawa, Mamoru ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b DNAVEC Corporation   (Japan)

Author keywords

AAV; Adenovirus; Cystic fibrosis; Gene therapy; Lentivirus; Sendai virus

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS VECTOR;

ARTICLE; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; NONHUMAN; NOSE MUCOSA; PROMOTER REGION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 79251471162     PISSN: None     EISSN: 11791624     Source Type: Book Series    
DOI: 10.2147/VAAT.S8887     Document Type: Article

References (116)

1. Welsh M, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, et al, editors. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill; 2001: 5121-5188.
2. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-1073.
3. Alton EW, Middleton PG, Caplen NJ, et al. Non-invasive liposomemediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet. 1993;5(2):135-142.
4. Drumm ML, Pope HA, Cliff WH, et al. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell. 1990;62(6): 1227-1233.
5. Griesenbach U, Alton EW. UK Cystic Fibrosis Gene Therapy Consortium. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev. 2009; 61(2): 128-139.
6. Sanders N, Rudolph C, Braeckmans K, de Smedt SC, Demeester J.Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev. 2009;61(2):115-127.
7. Stern M, Ulrich K, Geddes DM, Alton EW. Poly (D, L-lactide-co- glycolide)/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo. Gene Ther. 2003;10(16):1282-1288.
8. Yonemitsu Y, Kitson C, Ferrari S, et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol. 2000;18(9):970-973.
9. Sinn PL, Shah AJ, Donovan MD, McCray PB Jr. Viscoelastic gel formulationsenhance airway epithelial gene transfer with viral vectors. Am J Respir Cell Mol Biol. 2005;32(5):404-410.
10. Griesenbach U, Meng C, Farley R, et al. The use of carboxymethylcellulosegel to increase non-viral gene transfer in mouse airways. Biomaterials. 2010;31(9):2665-2672.
11. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immuneresponses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999;6(9):1574-1583.
12. McLachlan G, Davies LA, Gordon C, et al. Repeat aerosol delivery of concentrated PEI/pDNA to the sheep lung [abstract]. Mol Ther. 2010;18(S1):880.
13. Hyde SC, Southern KW, Gileadi U, et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 2000;7(13):1156-1165.
14. Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, Boucher RC. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J Virol. 1998; 72(7):6014-6023.
15. Ferrari S, Griesenbach U, Shiraki-Iida T, et al. A defectivenontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo. Gene Ther. 2004;11(22): 1659-1664.
16. Mudhakir D, Harashima H. Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. AAPS J. 2009;11(1):65-77.
17. Lam AP, Dean DA. Progress and prospects: nuclear import of nonviral vectors. Gene Ther. 2010;17(4):439-447.
18. Ding W, Zhang L, Yan Z, Engelhardt JF. Intracellular trafficking of adeno-associated viral vectors. Gene Ther. 2005;12(11):873-880.
19. Lee K, Ambrose Z, Martin TD, et al. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe. 2010;7(3):221-233.
20. Brunetti-Pierri N, Ng P. Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther. 2008;15(8):553-560.
21. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell. 1993;75(2):207-216.
22. Walters RW, Grunst T, Bergelson JM, Finberg RW, Welsh MJ, Zabner J. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem. 1999;274(15):10219-10226.
23. Weiss DJ, Beckett T, Bonneau L, Young J, Kolls JK, Wang G. Transient increase in lung epithelial tight junction permeability: an additional mechanism for enhancement of lung transgene expression by perfluorochemical liquids. Mol Ther. 2003;8(6):927-935.
24. Koehler DR, Frndova H, Leung K, et al. Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter. J Gene Med. 2005;7(11):1409-1420.
25. Price AR, Limberis MP, Wilson JM, Diamond SL. Pulmonary delivery of adenovirus vector formulated with dexamethasone-spermine facilitates homologous vector re-administration. Gene Ther. 2007; 14(22):1594-1604.
26. Chirmule N, Raper SE, Burkly L, et al. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions. J Virol. 2000;74(7):3345-3352.
27. Kolb M, Inman M, Margetts PJ, Galt T, Gauldie J. Budesonide enhances repeated gene transfer and expression in the lung with adenoviral vectors. Am J Respir Crit Care Med. 2001;164(5):866-872.
28. Flotte TR, Ng P, Dylla DE, et al. Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther. 2007;15(2):229-241.
29. Koehler DR, Sajjan U, Chow YH, et al. Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia. Proc Natl Acad Sci U S A. 2003; 100(26):15364-15369.
30. van Heeckeren AM, Scaria A, Schluchter MD, Ferkol TW, Wadsworth S, Davis PB. Delivery of CFTR by adenoviral vector to cystic fibrosis mouse lung in a model of chronic Pseudomonas aeruginosa lung infection. Am J Physiol Lung Cell Mol Physiol. 2004;286(4):L717-L726.
31. Larson JE, Morrow SL, Happel L, Sharp JF, Cohen JC. Reversal of cystic fibrosis phenotype in mice by gene therapy in utero. Lancet. 1997;349(9052):619-620.
32. Buckley SM, Waddington SN, Jezzard S, et al. Intra-amniotic delivery of CFTR-expressing adenovirus does not reverse cystic fibrosis phenotype in inbred CFTR-knockout mice. Mol Ther. 2008;16(5): 819-824.
33. Davies LA, Varathalingam A, Painter H, et al. Adenovirus-mediated in utero expression of CFTR does not improve survival of CFTR knockout mice. Mol Ther. 2008;16(5):812-818.
34. Meyerholz DK, Stoltz DA, Pezzulo AA, Welsh MJ. Pathology of gastrointestinal organs in a porcine model of cystic fibrosis. Am J Pathol. 2010;176(3):1377-1389.
35. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol. 1998;72(11):8568-8577.
36. Flotte TR. Recent developments in recombinant AAV-mediated gene therapy for lung diseases. Curr Gene Ther. 2005;5(3):361-366.
37. McCarty DM, Young SM Jr, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet. 2004;38:819-845.
38. Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest. 2004; 125(2):509-521.
39. Moss RB, Milla C, Colombo J, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther. 2007;18(8):726-732.
40. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005;5(3):285-297.
41. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther. 2009;17(2):294-301.
42. Xie Q, Bu W, Bhatia S, et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A. 2002;99(16):10405-10410.
43. Shi W, Bartlett JS. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther. 2003;7(4):515-525
44. White AF, Mazur M, Sorscher EJ, Zinn KR, Ponnazhagan S. Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells. Hum Gene Ther. 2008;19(12):1407-1414.
45. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol. 2006;24(2):198-204.
46. Excoffon KJ, Koerber JT, Dickey DD, et al. Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc Natl Acad Sci U S A. 2009;106(10):3865-3870.
47. Li W, Zhang L, Johnson JS, et al. Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther. 2009;17(12):2067-2077.
48. Liu X, Luo M, Guo C, Yan Z, Wang Y, Engelhardt JF. Comparative biology of rAAV transduction in ferret, pig and human airway epithelia. Gene Ther. 2007;14(21):1543-1548.
49. Ding W, Yan Z, Zak R, Saavedra M, Rodman DM, Engelhardt JF. Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia. J Virol. 2003;77(13):7361-7366.
50. Yan Z, Lei-Butters DC, Zhang Y, Zak R, Engelhardt JF. Hybrid adenoassociated virus bearing nonhomologous inverted terminal repeats \enhances dual-vector reconstruction of minigenes in vivo. Hum Gene Ther. 2007;18(1):81-87.
51. Zhang LN, Karp P, Gerard CJ, et al. Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway. Mol Ther. 2004;10(6):990-1002.
52. Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther. 2001;4(4):383-391.
53. Halbert CL, Allen JM, Miller AD. Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat Biotechnol. 2002;20(7):697-701.
54. Song Y, Lou HH, Boyer JL, et al. Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6.2-mediated segmental trans-splicing. Hum Gene Ther. 2009;20(3):267-281.
55. Ostedgaard LS, Rokhlina T, Karp PH, et al. A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. Proc Natl Acad Sci U S A. 2005; 102(8):2952-2957.
56. Fischer AC, Smith CI, Cebotaru L, et al. Expression of a truncated cystic fibrosis transmembrane conductance regulator with an AAV5-pseudotyped vector in primates. Mol Ther. 2007;15(4): s756-763.
57. Mueller C, Torrez D, Braag S, et al. Partial correction of the CFTRdependent ABPA mouse model with recombinant adeno-associated virus gene transfer of truncated CFTR gene. J Gene Med. 2008; 10(1):51-60.
58. Allocca M, Doria M, Petrillo M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest. 2008;118(5):1955-1964.
59. Halbert CL, Lam SL, Miller AD. High-efficiency promoter-dependent transduction by adeno-associated virus type 6 vectors in mouse lung. Hum Gene Ther. 2007;18(4):344-354.
60. Beck SE, Jones LA, Chesnut K, et al. Repeated delivery of adenoassociated virus vectors to the rabbit airway. J Virol. 1999;73(11): 9446-9455.
61. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol. 1997;71(8):5932-5941.
62. Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol. 2000;74(3):1524-1532.
63. Auricchio A, O'Connor E, Weiner D, et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest. 2002;110(4):499-504.
64. Fischer AC, Beck SE, Smith CI, et al. Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. Mol Ther. 2003;8(6):918-926.
65. Halbert CL, Madtes DK, Vaughan AE, et al. Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. Mol Ther. 2010;18(6): 1165-1172.
66. Liu X, Luo M, Guo C, et al. Analysis of adeno-associated virus progenitor cell transduction in mouse lung. Mol Ther. 2009;17(2): 285-293.
67. Buff SM, Yu H, McCall JN, et al. IL-10 delivery by AAV5 vector attenuates inflammation in mice with pseudomonas pneumonia. Gene Ther. 2010;17(5):567-576.
68. Mueller C, Strayer MS, Sirninger J, et al. In vitro and in vivo functional characterization of gutless recombinant SV40-derived CFTR vectors. Gene Ther. 2010;17(2):227-237.
69. Kondo R, Feitelson MA, Strayer DS. Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Gene Ther. 1998;5(5):575-582.
70. Zhang L, Bukreyev A, Thompson CI, et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol. 2005;79(2):1113-1124.
71. Zhang L, Button B, Gabriel SE, et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol. 2009;7(7):e1000155.
72. Kwilas AR, Yednak MA, Zhang L, et al. Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro. J Virol. 2010;84(15):7770-7781.
73. Okada Y. Sendai virus-induced cell fusion. Methods Enzymol. 1993; 221:18-41.
74. Ferrari S, Griesenbach U, Iida A, et al. Sendai virus-mediated CFTR gene transfer to the airway epithelium. Gene Ther. 2007; 14(19):1371-1379.
75. Griesenbach U, Cassady RL, Ferrari S, et al. The nasal epithelium as a factory for systemic protein delivery. Mol Ther. 2002;5(2):98-103.
76. Li HO, Zhu YF, Asakawa M, et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol. 2000;74(14):6564-6569.
77. Inoue M, Tokusumi Y, Ban H, et al. Nontransmissible virus-like particle formation by F-deficient Sendai virus is temperature sensitive and reduced by mutations in M and HN proteins. J Virol. 2003;77(5):3238-3246.
78. Griesenbach U, McLachlan G, Owaki T, et al. Validation of recombinant Sendai virus in a non-natural host model. Gene Ther. 2010;In press.
79. Griesenbach U, Geddes DM, Alton EW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther. 2006;13(14):1061-1067.
80. Zhang Q, Li Y, Shi Y, Zhang Y. HVJ envelope vector, a versatile delivery system: its development, application, and perspectives. Biochem Biophys Res Commun. 2008;373(3):345-349.
81. Kaneda Y, Nakajima T, Nishikawa T, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther. 2002;6(2):219-226.
82. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8): 348-362.
83. Seki T, Yuasa S, Oda M, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 2010;7(1):11-14.
84. Rakonczay Z Jr, Hegyi P, Hasegawa M, et al. CFTR gene transfer to human cystic fibrosis pancreatic duct cells using a Sendai virus vector. J Cell Physiol. 2008;214(2):442-455.
85. Ignath I, Hegyi P, Venglovecz V, et al. CFTR expression but not Cl- transport is involved in the stimulatory effect of bile acids on apical Cl-/HCO3- exchange activity in human pancreatic duct cells. \Pancreas. 2009;38(8):921-929.
86. Engelhardt JF, Yankaskas JR, Wilson JM. In vivo retroviral gene transfer into human bronchial epithelia of xenografts. J Clin Invest. 1992;90(6):2598-2607.
87. Kobayashi M, Iida A, Ueda Y, Hasegawa M. Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J Virol. 2003;77(4):2607-2614.
88. Mitomo K, Griesenbach U, Inoue M, et al. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther. 2010;18(6):1173-1182.
89. Sinn PL, Arias AC, Brogden KA, McCray PB Jr. Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J Virol. 2008;82(21):10684-10692.
90. McKay T, Patel M, Pickles RJ, Johnson LG, Olsen JC. Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther. 2006;13(8):715-724.
91. Sinn PL, Sauter SL, McCray PB Jr. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther. 2005;12(14):1089-1098.
92. Limberis M, Anson DS, Fuller M, Parsons DW. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther. 2002;13(16):1961-1970.
93. Cmielewski P, Anson DS, Parsons DW. Lysophosphatidylcholine as an adjuvant for lentiviral vector mediated gene transfer to airway epithelium: effect of acyl chain length. Respir Res. 2010; 11(1):84.
94. Medina MF, Kobinger GP, Rux J, et al. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol Ther. 2003;8(5):777-789.
95. Stocker AG, Kremer KL, Koldej R, Miller DS, Anson DS, Parsons DW. Single-dose lentiviral gene transfer for lifetime airway gene expression. J Gene Med. 2009;11(10):861-867.
96. Rawlins EL, Hogan BL. Ciliated epithelial cell lifespan in the mouse trachea and lung. Am J Physiol Lung Cell Mol Physiol. 2008; 295(1):L231-L234.
97. Griesenbach U, Mitomo K, Inoue M, et al. Repeat administration of Sendai virus-F/HN pseudotyped lentivirus vector to the respiratory epithelium is feasible [abstract]. Mol Ther. 2008;1(16):A754.
98. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(9):3143-3150.
99. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998; 72(12):9873-9880.
100. Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest. 2009;119(4):964-975.
101. Wanisch K, Yanez-Munoz RJ. Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther. 2009;17(8):1316-1332.
102. Su K, Wang D, Ye J, Kim YC, Chow SA. Site-specific integration of retroviral DNA in human cells using fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc-finger protein E2C. Methods. 2009;47(4): 269-276.
103. Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc. 2009;4(4):495-505.
104. Ikeda Y, Takeuchi Y, Martin F, Cosset FL, Mitrophanous K, Collins M. Continuous high-titer HIV-1 vector production. Nat Biotechnol. 2003;21(5):569-572.
105. Denyer J, Dyche T. The Adaptive Aerosol Delivery (AAD) technology:past, present, and future. J Aerosol Med Pulm Drug Deliv. 2010;23 Suppl 1:S1-S10.
106. Beck SE, Laube BL, Barberena CI, et al. Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques. Mol Ther. 2002;6(4):546-554.
107. Buckley SM, Howe SJ, Sheard V, et al. Lentiviral transduction of the murine lung provides efficient pseudotype and developmental stage-dependent cell-specific transgene expression. Gene Ther. 2008; 15(16):1167-1175.
108. Mishra S, Wang X, Smiley N, et al. Genetic modification of airway progenitors following lentiviral gene delivery to the amniotic fluid of murine fetuses. Am J Respir Cell Mol Biol. 2010: Jun 25 [Epub ahead of print].
109. Sage EK, Leobinger MR, Polak J, Janes SM. The role of bone marrowderived stem cells in lung regeneration and repair. In: Melton D, Girad L, editors. StemBook. Cambridge (MA): Harvard Stem Cell Institute; 2008.
110. Wilson AA, Murphy GJ, Hamakawa H, et al. Amelioration of emphysema in mice through lentiviral transduction of long-lived pulmonary alveolar macrophages. J Clin Invest. 2010;120(1): 379-389.
111. Griese M, Latzin P, Kappler M, et al. Alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J. 2007;29(2):240-250.
112. Huang HY, Lee CC, Chiang BL. Short hairpin RNAs against eotaxin or interleukin-5 decrease airway eosinophilia and hyper-responsiveness in a murine model of asthma. J Gene Med. 2009;11(2): 112-118.
113. Scherr M, Venturini L, Eder M. Lentiviral vector-mediated expression of pre-miRNAs and antagomiRs. Methods Mol Biol. 2010;614: 175-185.
114. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med. 2004;10(5):487-493.
115. Sheridan MB, Fong P, Groman JD, et al. Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome. Hum Mol Genet. 2005;14(22):3493-3498.
116. Griesenbach U, Wasowicz MY, Smith SN, et al. Endpoint assay development and validation of non-viral gene transfer agents in CF mice [abstract]. Pediatr Pulmol. 2005;S28:270.